After dropping so-so early-stage results on its dual GLP-1/GLP-2 agonist earlier this year, fierce competition in the obesity treatment scene has persuaded Zealand Pharma to aim its development engine ...
Orforglipron, a small-molecule, nonpeptide oral glucagon-like peptide-1 (GLP-1) receptor agonist, is being investigated as a treatment for obesity. In this phase 3, multinational, randomized, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results